Tocagen licenses immunotherapy to ApolloBio for $16M upfront; WuXi AppTec unveils expanded lab testing site in … – Endpoints News
Endpoints News |
Tocagen licenses immunotherapy to ApolloBio for $16M upfront; WuXi AppTec unveils expanded lab testing site in …
Endpoints News San Diego-based Tocagen $TOCA has inked a licensing deal with ApolloBio, giving an affiliate of the Beijing-based company an exclusive license to develop and commercialize its cancer-selective immunotherapy. Tocagen's treatment, called Toca 511 & Toca … Tocagen (TOCA) Reports License Agreement with Beijing Apollo … |
